ArticlePloS one2023
Prediction of pathological complete response to neoadjuvant chemotherapy in locally advanced breast cancer by using a deep learning model with 18F-FDG PET/CT.
Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Artificial intelligence-assisted PET imaging for predicting neoadjuvant chemotherapy response in breast cancer: a systematic review and meta-analysis.European journal of nuclear medicine and molecular imaging · 2026Pooled it
- Diagnostic accuracy of artificial intelligence-assisted 18f-fdg pet/ct for predicting pathological complete response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis.Annals of nuclear medicine · 2026Pooled it
- Multimodal deep learning for predicting neoadjuvant treatment outcomes in breast cancer: a systematic review.Biology direct · 2025Pooled it
- Multi-omics deep learning improves FDG PET-CT-based long-term prognostication of breast cancer.NPJ precision oncology · 2026Article
- [Artificial intelligence in predicting pathological complete response to neoadjuvant chemotherapy for breast cancer: current advances and challenges].Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi · 2025Review
- Article
- Dendritic Cell Subpopulations Are Associated with Prognostic Characteristics of Breast Cancer after Neoadjuvant Chemotherapy-An Observational Study.International journal of molecular sciences · 2023Observational
- GRACE-ViT: Grouped Recalibration With Adaptive Contextual Emphasis for Breast Cancer Neoadjuvant Chemotherapy Response Prediction.Technology in cancer research & treatmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe aim of the study is 18F-FDG PET/CT imaging by using deep learning method are predictive for pathological complete response pCR after Neoadjuvant chemotherapy (NAC) in locally advanced breast cancer (LABC).
introductionNAC is the standard treatment for locally advanced breast cancer (LABC). Pathological complete response (pCR) after NAC is considered a good predictor of disease-free survival (DFS) and overall survival (OS).Therefore, there is a need to develop methods that can predict the pCR at the time of diagnosis.
methodsThis article was designed as a retrospective chart study.For the convolutional neural network model, a total of 355 PET/CT images of 31 patients were used. All patients had primary breast surgery after completing NAC.
resultsPathological complete response was obtained in a total of 9 patients. The study results show that our proposed deep convolutional neural networks model achieved a remarkable success with an accuracy of 84.79% to predict pathological complete response.
conclusionIt was concluded that deep learning methods can predict breast cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.